Citigroup’s Niagen Bioscience NAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $139K | Buy |
43,497
+30,078
| +224% | +$122K | ﹤0.01% | 4512 |
|
|
2026
Q1 | $59.2K | Sell |
13,419
-39,361
| -75% | -$213K | ﹤0.01% | 4461 |
|
|
2025
Q4 | $336K | Buy |
52,780
+47,413
| +883% | +$330K | ﹤0.01% | 3763 |
|
|
2025
Q3 | $50.1K | Sell |
5,367
-13,243
| -71% | -$134K | ﹤0.01% | 4502 |
|
|
2025
Q2 | $268K | Sell |
18,610
-16,656
| -47% | -$164K | ﹤0.01% | 3927 |
|
|
2025
Q1 | $243K | Sell |
35,266
-4,695
| -12% | -$29.5K | ﹤0.01% | 4085 |
|
|
2024
Q4 | $212K | Buy |
39,961
+4,636
| +13% | +$25.4K | ﹤0.01% | 4378 |
|
|
2024
Q3 | $129K | Buy |
35,325
+24,673
| +232% | +$77.7K | ﹤0.01% | 4636 |
|
|
2024
Q2 | $29.1K | Sell |
10,652
-52,217
| -83% | -$175K | ﹤0.01% | 4880 |
|
|
2024
Q1 | $219K | Buy |
+62,869
| New | +$116K | ﹤0.01% | 3978 |
|
|
2022
Q4 | – | Sell |
-1
| Closed | – | – | 6000 |
|
|
2022
Q3 | $0 | Sell |
1
-906
| -100% | -$1.46K | ﹤0.01% | 6420 |
|
|
2022
Q2 | $2K | Sell |
907
-3,009
| -77% | -$5.88K | ﹤0.01% | 5934 |
|
|
2022
Q1 | $10K | Sell |
3,916
-8,021
| -67% | -$21.9K | ﹤0.01% | 5555 |
|
|
2021
Q4 | $45K | Buy |
11,937
+6,598
| +124% | +$35.6K | ﹤0.01% | 5124 |
|
|
2021
Q3 | $33K | Buy |
5,339
+2,139
| +67% | +$17.6K | ﹤0.01% | 4986 |
|
|
2021
Q2 | $31K | Buy |
3,200
+471
| +17% | +$4.11K | ﹤0.01% | 5071 |
|
|
2021
Q1 | $25K | Sell |
2,729
-5,157
| -65% | -$40.9K | ﹤0.01% | 5120 |
|
|
2020
Q4 | $38K | Buy |
7,886
+5,928
| +303% | +$28.9K | ﹤0.01% | 6233 |
|
|
2020
Q3 | $8K | Sell |
1,958
-3,555
| -64% | -$17.1K | ﹤0.01% | 6785 |
|
|
2020
Q2 | $25K | Sell |
5,513
-6,499
| -54% | -$29.1K | ﹤0.01% | 6456 |
|
|
2020
Q1 | $39K | Buy |
12,012
+3,789
| +46% | +$14.5K | ﹤0.01% | 6209 |
|
|
2019
Q4 | $35K | Buy |
8,223
+2,892
| +54% | +$10.3K | ﹤0.01% | 6609 |
|
|
2019
Q3 | $21K | Sell |
5,331
-5,380
| -50% | -$22.9K | ﹤0.01% | 6719 |
|
|
2019
Q2 | $50K | Buy |
10,711
+277
| +3% | +$1.18K | ﹤0.01% | 6483 |
|
|
2019
Q1 | $43K | Buy |
10,434
+336
| +3% | +$1.21K | ﹤0.01% | 6456 |
|
|
2018
Q4 | $35K | Sell |
10,098
-467
| -4% | -$1.62K | ﹤0.01% | 6523 |
|
|
2018
Q3 | $45K | Buy |
10,565
+5,037
| +91% | +$21.7K | ﹤0.01% | 6618 |
|
|
2018
Q2 | $21K | Buy |
+5,528
| New | +$21K | ﹤0.01% | 6905 |
|
|
2017
Q3 | – | Sell |
-1
| Closed | – | – | 7475 |
|
|
2017
Q2 | $0 | Sell |
1
-82
| -99% | -$260 | ﹤0.01% | 7513 |
|
|
2017
Q1 | $0 | Sell |
83
-28,723
| -100% | -$81.5K | ﹤0.01% | 7365 |
|
|
2016
Q4 | $95K | Buy |
28,806
+26,457
| +1,126% | +$71.9K | ﹤0.01% | 5808 |
|
|
2016
Q3 | $7K | Sell |
2,349
-537
| -19% | -$1.97K | ﹤0.01% | 6683 |
|
|
2016
Q2 | $12K | Buy |
+2,886
| New | +$13.7K | ﹤0.01% | 6461 |
|
Other funds holding NAGE
SW
TCM
Citigroup's NAGE Position: Q2 2026 in Review
Citigroup increased its Niagen Bioscience (NAGE) stake by 224% in Q2 2026, buying an estimated $122K and bringing the position to 43,497 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #4512.
Citigroup first reported a position in NAGE in Q2 2016 and has held it in 33 quarters since. The position peaked at $336K in Q4 2025. 139 funds tracked by Wall St. Rank hold NAGE as of Q2 2026.
- Citigroup held 43,497 shares of Niagen Bioscience worth $139K as of Q2 2026.
- Citigroup bought 30,078 Niagen Bioscience shares in Q2 2026, an estimated $122K.
- Niagen Bioscience made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4512 holding.
- Citigroup first reported a position in Niagen Bioscience in Q2 2016 and has held it in 33 quarters since.
- Citigroup's Niagen Bioscience position peaked at $336K in Q4 2025.
- 139 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2026.
Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.